(Alliance News) - Futura Medical PLC on Friday said it expects 2024 revenue and post-tax profit ahead of guidance, but warned of 2025 sales below market expectations, due to slow uptake in the US of its erectile dysfunction treatment. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
Futura Medical PLC - Guildford, Surrey-based sexual health products - Shares rise 4.5% on Wednesday as Futura reports positive results from a 'sensory' study of its WSD4000 treatment for sexual dysfunction in women. Futura explains that a sensory study assesses how healthy volunteers perceive product characteristics through their senses. The study involved 67 women with some degree of sexual dysfunction, and WSD4000 produced a positive change in a majority of them after four weeks. "Following the success of the study, alongside market research on the size of the opportunity following commercialisation, the board is recommending to proceed with an early feasibility study during H1 2025," Futura says. Read More
(Alliance News) - Futura Medical PLC on Monday said it has progressed the development of its new product pipeline, including treatments for sexual dysfunction in both men and women. Read More
Futura Medical PLC - Surrey-based sexual health products company - Announces that the next milestone payment of USD5.0 million, due under its agreement with Haleon PLC, has been triggered by Haleon's distribution of online pre-orders and the availability of Eroxon in US retailers. Eroxon is a fast-acting gel used to treat erectile dysfunction, which has been available without a prescription in UK pharmacies since March last year. Futura Medical struck a licensing deal with Haleon for the gel in July 2023, which has led to its availability in the US from October this year. Futura Medical expects to receive the payment from Haleon shortly. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Futura Medical PLC - sexual health products company - Says Eroxon is available for pre-order online, and will also be available in US stores from October. Eroxon is a fast-acting gel used to treat erectile dysfunction, which has been available without a prescription in UK pharmacies since March last year. More recently, Futura struck a licensing deal with Haleon PLC for the gel, which has led to its availability in the US. Read More
(Correcting that US financial markets will be closed for Labor Day.) Read More
(Alliance News) - Stock prices in London were red at midday on Monday, taking a tumble even as data showed continued recovery for the UK manufacturing sector. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Futura Medical PLC on Wednesday celebrated its "first set out meaningful revenues" in 2023, as sales for its erectile dysfunction treatment climbed. Read More
Futura Medical PLC - Guildford, England-based pharmaceutical company focused on sexual health products - Confirms that lead product Eroxon will from March 1 be available on prescription in England and Wales for the treatment of erectile dysfunction. Eroxon is a gel-based treatment designed to help the user obtain an erection, and serves as an alternative for people who are unwilling or unable to use medications like Viagra. Eroxon has also been available without a prescription in UK pharmacies since March last year. Read More
(Alliance News) - Stock prices in London pushed higher on Tuesday, with the FTSE 100 registering its first rise in four trading days, with oil major BP the star performer. Read More
(Alliance News) - Futura Medical PLC on Tuesday reported its first revenues in 2023, thanks to the successful global roll-out of Eroxon. Read More
(Alliance News) - Futura Medical PLC on Monday said that it has extended its exclusive licensing agreement with Cooper Consumer Health Group, a European self-care organisation, to January 2029. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More